Kyrillos Jean-Claude
Kyrillos Jean-Claude's purchase track record
Kyrillos Jean-Claude has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/7/2025 | TNDM | $191K | +15.7% | -30.0% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Piper Sandler cuts Envista price target to $26, maintains Neutral. Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.
Transaction History
| TNDM | ▲ Buy | Option Exercise | 1,010 | $0 | 8/15/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 535 | $12K | 8/15/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 1,926 | $29K | 7/15/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 3,636 | $0 | 7/15/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,038 | $0 | 5/15/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 2,139 | $27K | 5/15/2026 | View on chart |
| TNDM | ▲ Buy | Grant | 434 | $5K | 5/15/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 3,636 | $0 | 4/15/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 1,926 | $40K | 4/15/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 3,636 | $0 | 1/15/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 2,118 | $45K | 1/15/2026 | View on chart |
| TNDM | ▲ Buy | Grant | 160 | $2K | 11/17/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 1,301 | $19K | 10/15/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 3,636 | $0 | 10/15/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 5,205 | $79K | 7/15/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 14,545 | $0 | 7/15/2025 | View on chart |
| TNDM | ▲ Buy | Grant | 171 | $3K | 5/15/2025 | View on chart |
| TNDM | ▲ Buy | Open Market | 10,538 | $191K | 3/7/2025 | View on chart |
| NVST | ▼ Sell | Tax Withholding | 2,796 | $107K | 2/25/2023 | View on chart |
| NVST | ▲ Buy | Grant | 5,560 | $0 | 2/25/2023 | View on chart |
| NVST | ▼ Sell | Tax Withholding | 2,261 | $110K | 2/25/2022 | View on chart |
| NVST | ▲ Buy | Grant | 4,380 | $0 | 2/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.